Bhushan N. Kharbikar

Bhushan N. Kharbikar

Auto-generated profile, based on publicly available information

Bhushan N. Kharbikar

Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2025 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
HNHai P. Nguyen
Hai P. Nguyen
KAKelly An
Kelly An
YIYusuke Ito
Yusuke Ito
BKBhushan N. Kharbikar
Bhushan N. Kharbikar
RSRory Sheng
Rory Sheng
NANadav Ahituv
Nadav Ahituv
Tumors exhibit an increased ability to obtain and metabolize nutrients. Here, we implant engineered adipocytes that outcompete tumors for nutrients and show that they can substantially reduce cancer progression, a technology termed adipose manipulation transplantation (AMT). Adipocytes engineered to use increased amounts of glucose and fatty acids by upregulating UCP1 were placed alongside cancer cells or xenografts, leading to significant cancer suppression. Transplanting modulated adipose organoids in pancreatic or breast cancer genetic mouse models suppressed their growth and decreased angiogenesis and hypoxia. Co-culturing patient-derived engineered adipocytes with tumor organoids from dissected human breast cancers significantly suppressed cancer progression and proliferation. In addition, cancer growth was impaired by inducing engineered adipose organoids to outcompete tumors using tetracycline or placing them in an integrated cell-scaffold delivery platform and implanting them next to the tumor. Finally, we show that upregulating UPP1 in adipose organoids can outcompete a uridine-dependent pancreatic ductal adenocarcinoma for uridine and suppress its growth, demonstrating the potential customization of AMT.

20 January 2023 in Science Advances
Verified
Journal Article
Closed access
JFJoel Finbloom
Joel Finbloom
PRPreethi Raghavan
Preethi Raghavan
MKMichael Kwon
Michael Kwon
BKBhushan N. Kharbikar
Bhushan N. Kharbikar
MYMichelle A. Yu
Michelle A. Yu
TDTejal A Desai
Tejal A Desai
Bacterial biofilm infections, particularly those of Pseudomonas aeruginosa (PA), have high rates of antimicrobial tolerance and are commonly found in chronic wound and cystic fibrosis lung infections. Combination therapeutics that act synergistically can overcome antimicrobial tolerance; however, the delivery of multiple therapeutics at relevant dosages remains a challenge. We therefore developed a nanoscale drug carrier for antimicrobial codelivery by combining approaches from polyelectrolyte nanocomplex (NC) formation and layer-by-layer electrostatic self-assembly. This strategy led to NC drug carriers loaded with tobramycin antibiotics and antimicrobial silver nanoparticles (AgTob-NCs). AgTob-NCs displayed synergistic enhancements in antimicrobial activity against both planktonic and biofilm PA cultures, with positively charged NCs outperforming negatively charged formulations. NCs were evaluated in mouse models of lung infection, leading to reduced bacterial burden and improved survival outcomes. This approach therefore shows promise for nanoscale therapeutic codelivery to treat recalcitrant bacterial infections.

23 October 2023 in npj Regenerative Medicine
Verified
Journal Article
Open access
PDF file
PMPriya Mohindra
Priya Mohindra
JZJustin X. Zhong
Justin X. Zhong
QFQizhi Fang
Qizhi Fang
DCDarnell L. Cuylear
Darnell L. Cuylear
CHCindy Huynh
Cindy Huynh
TDTejal A Desai
Tejal A Desai
Heart failure (HF) remains a global public health burden and often results following myocardial infarction (MI). Following injury, cardiac fibrosis forms in the myocardium which greatly hinders cellular function, survival, and recruitment, thus severely limits tissue regeneration. Here, we leverage biophysical microstructural cues made of hyaluronic acid (HA) loaded with the anti-fibrotic proteoglycan decorin to more robustly attenuate cardiac fibrosis after acute myocardial injury. Microrods showed decorin incorporation throughout the entirety of the hydrogel structures and exhibited first-order release kinetics in vitro. Intramyocardial injections of saline (n = 5), microrods (n = 7), decorin microrods (n = 10), and free decorin (n = 4) were performed in male rat models of ischemia-reperfusion MI to evaluate therapeutic effects on cardiac remodeling and function. Echocardiographic analysis demonstrated that rats treated with decorin microrods (5.21% ± 4.29%) exhibited significantly increased change in ejection fraction (EF) at 8 weeks post-MI compared to rats treated with saline (−4.18% ± 2.78%, p < 0.001) and free decorin (−3.42% ± 1.86%, p < 0.01). Trends in reduced end diastolic volume were also identified in decorin microrod-treated groups compared to those treated with saline, microrods, and free decorin, indicating favorable ventricular remodeling. Quantitative analysis of histology and immunofluorescence staining showed that treatment with decorin microrods reduced cardiac fibrosis (p < 0.05) and cardiomyocyte hypertrophy (p < 0.05) at 8 weeks post-MI compared to saline control. Together, this work aims to contribute important knowledge to guide rationally designed biomaterial development that may be used to successfully treat cardiovascular diseases.

26 May 2021 in Current Opinion in Biomedical Engineering
Verified
Journal Article
Open access
BKBhushan N. Kharbikar
Bhushan N. Kharbikar
JZJustin X. Zhong
Justin X. Zhong
DCDarnell L. Cuylear
Darnell L. Cuylear
CPCynthia A. Perez
Cynthia A. Perez
TDTejal A Desai
Tejal A Desai
Tissue engineering strategies, notably biomaterials, can be modularly designed and tuned to match specific patient needs. Although many challenges within tissue engineering remain, the incorporation of diagnostic strategies to create theranostic (combined therapy and diagnostic) biomaterials presents a unique platform to provide dual monitoring and treatment capabilities and advance the field toward personalized technologies. In this review, we summarize recent developments in this young field of regenerative theranostics and discuss the clinical potential and outlook of these systems from a tissue engineering perspective. As the need for precision and personalized medicines continues to increase to address diseases in all tissues in a patient-specific manner, we envision that such theranostic platforms can serve these needs.

9 April 2021 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
FNU RAVINDER KUMARFNU RAVINDER KUMAR
FNU RAVINDER KUMAR
BKBhushan N. Kharbikar
Bhushan N. Kharbikar

9 July 2024 in Nature Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
APAmit Prabhakar
Amit Prabhakar
RKRahul Kumar
Rahul Kumar
MWMeetu Wadhwa
Meetu Wadhwa
PGPrajakta Ghatpande
Prajakta Ghatpande
JZJingkun Zhang
Jingkun Zhang
AHAkiko Hata
Akiko Hata